Switching patients with inflammatory arthritis from Etanercept (Enbrel(®)) to the biosimilar drug, SB4 (Benepali(®)): A single-centre retrospective observational study in the UK and a review of the literature

OBJECTIVE/AIM: SB4 (Benepali(®)), the Etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel(®). In 2016, the Rheumatology Department at Blackpool Teaching Hospitals switched the Etanercept patients, who gave consent, to SB4. A proportion of these pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Madenidou, Anastasia-Vasiliki, Jeffries, Andrew, Varughese, Sneha, Jones, Stephen, Sari-Kouzel, Hanadi, Veevers, Helen, Rao, Chandini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2019
Materias:
Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280874/
https://www.ncbi.nlm.nih.gov/pubmed/32524081
http://dx.doi.org/10.31138/mjr.30.1.69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280874/
https://www.ncbi.nlm.nih.gov/pubmed/32524081
http://dx.doi.org/10.31138/mjr.30.1.69

Ejemplares similares